Pressure BioSciences and Sage-N Research to Collaborate
News Mar 22, 2012
Pressure BioSciences, Inc. and Sage-N Research, Inc. have announced a collaboration to develop software applications on Sage-N's SORCERER™ Integrated Data Appliance platform.
The new software will be designed to work with PBI's patented and enabling pressure cycling technology ("PCT") system, a novel technology platform that is used to extract, among other biomolecules, integral cell membrane and other proteins for subsequent mass spectrometry analysis.
Integral cell membrane proteins are of significant clinical importance due to their roles in cell signal transduction in cancer, membrane transport disorders like Crohn's disease, pathogen invasion such as HIV, and their roles in other diseases and disorders.
Unfortunately, integral cell membrane proteins are traditionally very difficult to extract. In some cases, harsh chemicals are used in the extraction process, causing such severe protein degradation that subsequent proteomic analysis is compromised.
PBI's PCT Platform uses rapid cycles of low and ultra-high pressure to safely and effectively extract proteins from samples (including cell membranes) that are suitable for analysis by analytical methods such as mass spectrometry.
The PCT Platform also provides a high level of automation, speed, and reproducibility in the enzymatic breakdown of proteins. This allows the PCT-enhanced digestion to be completed in under an hour, compared to the standard four to twelve hours.
Richard T. Schumacher, President and CEO of PBI, said: "We plan to seamlessly integrate PBI's front- end PCT Sample Preparation System (instruments and consumables) with Sage-N's SORCERER back- end data reduction software. We expect to offer this bundled platform as an option to stand-alone sample preparation and data reduction methods used currently by the mass spectrometry laboratory. We believe that by bundling these enabling platforms, we will be offering a higher quality, more efficient, and less costly solution than they currently have for sample preparation and data reduction. Since the companies now target an identical market - the mass spectrometry laboratory - we expect to share a number of marketing and selling programs directed at this market going forward. Overall, we believe our new co- marketing program will reduce costs and increase sales for both PBI and Sage-N before the end of 2012."
"Mass spectrometry proteomics continues to evolve from a general-purpose protein identification technology to specialized applications, such as characterization of membrane proteins and detecting novel pathogens," noted David Chiang, Chairman of Sage-N Research.
Chiang continued, "Our SORCERER platform continues to evolve to meet the ever expanding IT needs of mass spectrometry labs by providing advanced companion tools for these applications."
Sage-N Research's SORCERER Integrated Data Appliance platform provides complementary software applications that are customized for each particular sample preparation chemistry.
This results in a semi- automated system for membrane and other protein analysis that can use any modern tandem mass spectrometer and liquid chromatography system.
Metabolomic Profiling Identifies Taurine as New MS TherapeuticNews
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies. The discovery also highlights the potential for a technique called “metabolomic profiling,” which can identify useful endogenous metabolites the body already makes in small quantities, such as taurine, for new applications in drug therapies.READ MORE
Physiochemical 'Fingerprint' of Parasitic 'American Murderer' UncoveredNews
With the help of using Atomic Force Microscopy and Time-of-Flight Secondary Ion Mass Spectrometry, the physical and chemical ‘fingerprint’ profile of a parasitic worm, dubbed the ‘American murderer,’ has been uncovered for the first time by researchers - a discovery that could allow for more effective and earlier treatment.READ MORE